Business Context and Reporting Period
Company: pSivida Corp. (Note: Input metadata referenced "Eyepoint, Inc.", but the filing text identifies the registrant as pSivida Corp.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2011
Business Overview: pSivida develops sustained-release drug delivery products for chronic eye diseases using two core technologies: Durasert and BioSilicon. The company relies on collaboration agreements for development and commercialization, primarily with Alimera Sciences (ILUVIEN), Bausch & Lomb (Retisert, Vitrasert), and Pfizer.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2011 | Nine Months Ended Mar 31, 2011 |
|---|---|---|
| Total Revenues | $360,000 | $1,250,000 |
| Net Loss | $(2,685,000) | $(8,488,000) |
| Loss Per Share (Basic/Diluted) | $(0.13) | $(0.45) |
| Cash and Cash Equivalents | $13,296,000 | (Balance Sheet Item) |
| Marketable Securities | $9,770,000 | (Balance Sheet Item) |
| Total Liquidity (Cash + Securities) | $23,066,000 | (Balance Sheet Item) |
| Accumulated Deficit | $(226,783,000) | (Balance Sheet Item) |
| Derivative Liabilities | $180,000 | (Balance Sheet Item) |
Note: All figures in thousands except per share data. No long-term debt is reported.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 30% ($155,000) for the quarter and 83% ($6.1 million) for the nine-month period compared to the prior year. This is primarily due to the completion of the performance obligation period for the Alimera collaboration agreement in December 2009, which previously generated significant revenue.
- Operating Expenses: Total operating expenses increased 4% ($121,000) for the quarter and 5% ($531,000) for the nine-month period. General and Administrative (G&A) expenses rose due to increased stock-based compensation and professional fees.
- Derivative Income: The company recorded a gain of $334,000 (quarter) and $1.13 million (nine months) from the change in fair value of derivative liabilities (A$-denominated warrants). This contrasts with a loss of $1.21 million in the prior nine-month period, driven by the expiration of warrants and the spread between share price and exercise prices.
- Capital Raise: In January 2011, the company completed a registered direct offering of 2.21 million shares and warrants, raising gross proceeds of $11.05 million (net proceeds approx. $10.1 million).
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing capital resources of $23.1 million are sufficient to fund operations into at least calendar year 2013.
- ILUVIEN Regulatory Status: The FDA issued a Complete Response Letter (CRL) in December 2010 regarding the New Drug Application (NDA) for ILUVIEN (licensed to Alimera). The FDA requested additional 36-month safety and efficacy data. Alimera reported submitting this data in May 2011. Approval is critical for a potential $25.0 million milestone payment and future royalties.
- Revenue Expectations: Absent FDA approval of ILUVIEN in fiscal year 2011, the company expects to record insignificant collaborative research revenue from Alimera. Royalty income from Bausch & Lomb is expected to continue declining.
- Key Risks:
- Failure to obtain FDA approval for ILUVIEN.
- Need for additional capital if ILUVIEN is not approved or commercialized successfully.
- Fluctuations in operating results due to the revaluation of derivative liabilities.
- Impairment of intangible assets (BioSilicon and Durasert technologies).
Investor Verification Checklist
- ILUVIEN Approval Timeline: Verify the status of the FDA's review of the 36-month data submitted by Alimera and the likelihood of approval.
- Cash Burn Rate: Confirm the company's ability to maintain operations through 2013 given the continued net losses and lack of significant near-term revenue.
- Derivative Liability Exposure: Monitor the remaining A$-denominated warrants (approx. 205,000 outstanding as of May 2011) and their impact on earnings volatility until expiration in July 2012.
- Intangible Asset Valuation: Assess the risk of future impairment charges on the $22.4 million in intangible assets if product development stalls.
- Collaboration Dependencies: Review the terms of the Alimera agreement regarding the $25 million milestone and the 20% profit share to understand future revenue potential.